Plasma leptin and adiposity during antipsychotic treatment of schizophrenia

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Dan W HauptJohn W Newcomer

Abstract

Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n=27), risperidone (n=24) or typical antipsychotics (n=21) and 124 healthy adult control subjects. ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and female...Continue Reading

Associated Clinical Trials

References

Aug 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·P B Mortensen, K Juel
Feb 1, 1996·American Journal of Epidemiology·D GallagherS B Heymsfield
Dec 1, 1996·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·F HubeH Hauner
Mar 10, 1998·Molecular Psychiatry·T BrömelJ Hebebrand
Jul 23, 1999·Schizophrenia Bulletin·J W NewcomerR Miller
Jul 28, 1999·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·D G BaskinM W Schwartz
Apr 15, 2000·Nature·M W SchwartzD G Baskin
Jun 24, 2000·Diabetes·C T Montague, S O'Rahilly
Sep 9, 2000·Schizophrenia Research·U OsbyP Sparén
Sep 21, 2000·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·G Del Rio
Jun 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·R P Tracy
Jul 4, 2001·The British Journal of Psychiatry : the Journal of Mental Science·A HerránJ L Vázquez-Barquero
Oct 20, 2001·Behavioural Brain Research·T MorimotoA Yamatodani
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Jan 16, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·J H ThakoreR Reznek
Feb 8, 2002·Gastroenterology·Iradj SobhaniAndré Bado
Jul 27, 2002·Science·Lora K HeislerJoel K Elmquist
Aug 29, 2002·Gastroenterology·Samuel KleinHarvey J Sugerman
Nov 8, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Trino Baptista, Serge Beaulieu
Nov 20, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·S MargeticR A Hill
Dec 10, 2002·Annual Review of Physiology·Roger H Unger
Dec 28, 2002·Diabetes Care·UNKNOWN Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
Dec 31, 2002·JAMA : the Journal of the American Medical Association·Ali H MokdadJames S Marks
Jan 15, 2004·American Journal of Physiology. Endocrinology and Metabolism·Nina EikelisMurray Esler
May 26, 2004·The American Journal of Clinical Nutrition·Cees de GraafHenk F J Hendriks
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Erin E Kershaw, Jeffrey S Flier

❮ Previous
Next ❯

Citations

May 29, 2007·Journal of Neural Transmission·A A van ElburgH van Engeland
Jun 7, 2005·Pharmacology, Biochemistry, and Behavior·Roselei FachinettoJoão B T Rocha
Jan 1, 2008·Schizophrenia Bulletin·Othman SentissiMarie-France Poirier
May 30, 2009·Diabetes, Obesity & Metabolism·Richard I G Holt, Robert C Peveler
Sep 20, 2006·Pharmacogenomics·Daniel J Müller, James L Kennedy
Oct 31, 2009·Psychiatric Genetics·Chadi A CalargeJanet A Schlechte
May 16, 2008·Journal of Clinical Psychopharmacology·Rocio Perez-IglesiasBenedicto Crespo-Facorro
Dec 5, 2009·CNS Drugs·Chaya G BhuvaneswarJonathan E Alpert
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Nov 30, 2011·International Journal of Psychiatry in Clinical Practice·Meng-Chang TsaiTiao-Lai Huang
Jul 1, 2010·Expert Review of Neurotherapeutics·Lawrence Maayan, Christoph U Correll
Jun 26, 2009·The Journal of Investigative Dermatology·Stephan TiedeRalf Paus
Jun 24, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kazuhide TanakaShigeto Yamawaki
Jun 27, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ayşen Esen-DanaciNesrin Ozlen
Jan 22, 2008·Schizophrenia Research·Hua JinDilip V Jeste
May 23, 2009·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·S Gentile
Feb 12, 2008·The American Journal of Medicine·Alan N Elias, Heather Hofflich
Jun 15, 2012·Journal of Psychopharmacology·Chao DengXu-Feng Huang
Jun 23, 2012·Journal of Psychopharmacology·Daniel B KurbanovIgor Elman
May 14, 2008·The Australian and New Zealand Journal of Psychiatry·Sanil Rege
Aug 19, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Palmiero MonteleoneMario Maj
Sep 25, 2018·Autism Research : Official Journal of the International Society for Autism Research·Ramkripa RaghavanXiaobin Wang
Mar 17, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Igor ElmanScott E Lukas
Feb 9, 2020·Lipids in Health and Disease·Francky Teddy EndombaJoel Noutakdie Tochie
Oct 6, 2007·Wiener medizinische Wochenschrift·Andreas BaranyiHans-Bernd Rothenhäusler
Mar 30, 2021·Frontiers in Psychiatry·Mark R Libowitz, Erika L Nurmi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here